07:00 , Aug 17, 2015 |  BC Week In Review  |  Clinical News

Nuedexta dextromethorphan/quinidine: Phase IV data

Top-line data from the open-label, U.S. Phase IV PRISM II trial in 367 patients with PBA showed that twice-daily 20/10 mg Nuedexta reduced mean CNS-LS score to 11.9 points at week 12 from 20.5 points...
08:00 , Jan 12, 2015 |  BioCentury  |  Finance

Buyside view XXIII: Milestones galore

Stephen Hansen, Associate Editor and Jennifer Rhodes, Staff Writer   Buyside view XXIII The maturation of the biotech sector over the past few years finds fund managers focusing on a slew of clinical milestones and...
08:00 , Dec 15, 2014 |  BioCentury  |  Finance

Avanir Chronicles

Avanir Chronicles Avanir chroniclesThe $17 takeout price Otsuka Pharmaceutical Co. Ltd. will pay for Avanir Pharmaceuticals Inc. (NASDAQ:AVNR) is only a 13% premium to the neurology play's close the day before the $3.5 billion deal...
08:00 , Dec 8, 2014 |  BC Week In Review  |  Company News

Avanir, Otsuka Pharmaceutical deal

Otsuka is acquiring Avanir for $17 per share in a deal valued at about $3.5 billion. The price represents a 13% premium to Avanir’s closing price of $15 on Dec. 1, before the deal was...
02:50 , Dec 3, 2014 |  BC Extra  |  Top Story

Otsuka buying Avanir for $3.5B

Otsuka Pharmaceutical Co. Ltd. (Tokyo, Japan) will acquire Avanir Pharmaceuticals Inc. (NASDAQ:AVNR) for $3.5 billion, or $17 per share. The price represents a 13% premium to Avanir's closing price of $15 on Dec. 1 before...
07:00 , Oct 20, 2014 |  BC Week In Review  |  Clinical News

Nuedexta dextromethorphan/quinidine: Additional Phase II data

Additional data from 218 AD patients in the modified intent-to-treat (mITT) population of the 10-week, double-blind, U.S. Phase II AVR-131 trial showed that oral AVP-923 significantly reduced agitation as measured by the agitation/aggression subscale score...
07:00 , Oct 6, 2014 |  BioCentury  |  Finance

3Q14 Stock Wrap-Up: Going big again

For the second quarter in a row, only the large caps finished in the black in 3Q14. In the over $5 billion segment, which was up 9%, gainers outnumbered decliners 22-9, while the decliners led...
02:25 , Sep 25, 2014 |  BC Extra  |  Financial News

Avanir raises $200.2M follow-on

Avanir Pharmaceuticals Inc. (NASDAQ:AVNR) raised $200.2 million through the sale of 18.2 million shares at $11 in a follow-on underwritten by J.P. Morgan; Deutsche Bank; and BofA Merrill Lynch. Avanir said Monday it planned to...
07:00 , Sep 22, 2014 |  BC Week In Review  |  Clinical News

Nuedexta dextromethorphan/quinidine: Phase II data

The 10-week, double-blind, U.S. Phase II AVR-131 trial in 220 AD patients showed that oral AVP-923 met the primary endpoint of reducing agitation as measured by the agitation/aggression subscale score of the NPI vs. placebo...
01:50 , Sep 16, 2014 |  BC Extra  |  Top Story

Avanir surges on AD agitation data

Investors added $1 billion in market cap to Avanir Pharmaceuticals Inc. (NASDAQ:AVNR) on Monday after the company's AVP-923 dextromethorphan/quinidine met the primary endpoint vs. placebo of reducing agitation in a Phase II trial to treat...